Department of Hematology and Oncology, Wilmot Cancer Center, University of Rochester Medical Center Rochester, NY, USA.
Front Endocrinol (Lausanne). 2012 Dec 13;3:163. doi: 10.3389/fendo.2012.00163. eCollection 2012.
There is evidence that inherited genetic variation affects both testicular germ cell tumor (TGCT) treatment outcome and risks of late-complications arising from cisplatin-based chemotherapy. Using a candidate gene approach, we examined associations of three genes involved in the cisplatin metabolism pathway, GSTP1, COMT, and TPMT, with TGCT outcome and cisplatin-induced neurotoxicity.
Our study population includes a subset of patients (n = 137) from a genome-wide association study at the University of Pennsylvania that evaluates inherited genetic susceptibility to TGCT. All patients in our study had at least one course of cisplatin-based chemotherapy with at least 1 year of follow-up. A total of 90 markers in GSTP1, COMT, and TPMT and their adjacent genomic regions (±20 kb) were analyzed for associations with refractory TGCT after first course of chemotherapy, progression-free survival (PFS), overall survival (OS), peripheral neuropathy, and ototoxicity.
After adjustment for multiple comparisons, one Single nucleotide polymorphism (SNP), rs2073743, in the flanking region (±20 kb) of COMT was associated with refractory TGCT after initial chemotherapy. This SNP lies within the intron region of the Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF). The G allele of rs2073743 predisposed patients to refractory disease with a relative risk of 2.6 (95% CI 1.1, 6.3; P = 0.03). Assuming recessive inheritance, patients with the GG genotype had 22.7 times higher risk (95% CI 3.3, 155.8; P = 0.04) of developing refractory disease when compared to those with the GC or CC genotypes. We found no association of our candidate genes with peripheral neuropathy, ototoxicity, PFS and OS.
This is the first study to suggest that germline genetic variants of ARVCF may affect TGCT outcome. The result of this study is hypothesis generating and should be validated in future studies.
有证据表明,遗传基因变异既影响睾丸生殖细胞瘤(TGCT)的治疗效果,又影响顺铂为基础的化疗引起的迟发性并发症的风险。我们采用候选基因的方法,研究了三个参与顺铂代谢途径的基因(GSTP1、COMT 和 TPMT)的遗传变异与 TGCT 结果和顺铂诱导的神经毒性之间的关联。
我们的研究人群包括宾夕法尼亚大学全基因组关联研究的一部分患者(n=137),该研究评估了遗传易感性对 TGCT 的影响。我们研究中的所有患者均至少接受了一个疗程的顺铂为基础的化疗,并且随访时间至少为 1 年。在 GSTP1、COMT 和 TPMT 及其相邻基因组区域(±20kb)中,共分析了 90 个标记物与首次化疗后 TGCT 的难治性、无进展生存期(PFS)、总生存期(OS)、周围神经病和耳毒性的相关性。
经过多重比较校正后,COMT 侧翼区域(±20kb)的一个单核苷酸多态性(SNP)rs2073743 与初始化疗后的难治性 TGCT 相关。该 SNP 位于 Armadillo Repeat 基因缺失的 Velco-Cardio-Facial 综合征(ARVCF)内含子区域。rs2073743 的 G 等位基因使患者易患难治性疾病,相对风险为 2.6(95%CI1.1,6.3;P=0.03)。假设隐性遗传,与 GC 或 CC 基因型相比,GG 基因型的患者发生难治性疾病的风险高 22.7 倍(95%CI3.3,155.8;P=0.04)。我们没有发现候选基因与周围神经病、耳毒性、PFS 和 OS 之间存在关联。
这是第一项表明 ARVCF 种系遗传变异可能影响 TGCT 结果的研究。该研究结果具有启发性,应在未来的研究中验证。